This bill keeps a federal ALS program running through 2031, extending research grants and efforts to speed new treatments to patients. It tightens safety reporting for drug studies, uses more evidence when deciding whether to renew grants, and lets some combined late-stage trials qualify. It also requires the FDA to publish a 5-year plan and later report on progress for ALS and other rare brain diseases.
